Health Care Stocks With A Long History Of Dividend Growth And Solid Yields Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Health care stocks with a robust track record of consistent dividend increases are particularly attractive for income-focused investors. This article highlights three companies — Amgen, Medtronic, and Pfizer — that exemplify strong dividend growth and offer solid yields. Amgen Amgen (NASDAQ:AMGN) is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. The company has paid consistent dividends for 14 years and raised them for 13 consecutive years. In December 2023, it announced a 5.6% increase in its quarterly dividend to $2.25 per share, or $9 annualized. The annual yield on the dividend is 2.89%. Over the past twelve months, the company generated $29.53 billion in revenues and $3.76 billion in net income. Trending: If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Medtronic Medtronic (NYSE:MDT) develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. In May 2024, the company raised its quarterly dividend by 1.40% to $0.70 per share, or $2.80 annualized, marking the 47th consecutive year of dividend increases. The annual yield on the dividend currently stands at 3.63%. Over the past twelve months, the company generated $32.36 billion in revenues and $3.67 billion in net income. Don’t Miss: Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York. Investing in its booming real estate market has never been more accessible. Pfizer Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical firms. While it historically sold many types of health care products and chemicals, prescription drugs and vaccines now account for the majority of sales. Top sellers include the pneumococcal vaccine Prevnar 13, the cancer drug Ibrance, and the cardiovascular treatment Eliquis. The company has paid 343 consecutive quarterly dividends. Its quarterly dividend is $0.42 per share, or $1.68 annualized, with a yield of 5.95%. Looking For Higher-Yield Opportunities? The current high-interest-rate environment has created an incredible opportunity for income-seeking investors to earn massive yields, but not through dividend stocks... Certain private market real estate investments are giving retail investors the opportunity to capitalize on these high-yield opportunities and Benzinga has identified some of the most attractive options for you to consider. For instance, the Ascent Income Fund from EquityMultiple targets stable income from senior commercial real estate debt positions and has a historical distribution yield of 12.1% backed by real assets. With payment priority and flexible liquidity options, the Ascent Income Fund is a cornerstone investment vehicle for income-focused investors. First-time investors with EquityMultiple can now invest in the Ascent Income Fund with a reduced minimum of just $5,000. Don't miss out on this opportunity to take advantage of high-yield investments while rates are high. Check out Benzinga's favorite high-yield offerings. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. This article Health Care Stocks With A Long History Of Dividend Growth And Solid Yields originally appeared on Benzinga.com
Health Care Stocks With A Long History Of Dividend Growth And Solid Yields
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...